K Ueda1, M Takahashi, K Ozawa, M Kinoshita. 1. First Department of Medicine, Shiga University of Medical Science, Seta Tsukinowacho, Otsu, Shiga, 520-2192, Japan.
Abstract
BACKGROUND: The plasma level of interleukin-6 (IL-6), a proinflammatory cytokine, has been reported to be elevated in patients with acute myocardial infarction (AMI). In addition to a specific cell-surface IL-6 receptor, a soluble IL-6 receptor (sIL-6R) exists in plasma as an extracellular domain of glycoprotein 80. The pathophysiologic roles of IL-6 and sIL-6R in AMI are still unknown. METHODS AND RESULTS: We measured plasma levels of IL-6 and sIL-6R in 17 patients with AMI to evaluate changes over time at 11 points in the acute phase and compared them with parameters of inflammation, myocardial injury, and atherosclerosis. IL-6 showed a triphasic increase with peaks at 3 hours (276.2 +/- 50.0 pg/mL), 2 days (153.6 +/- 35.7 pg/mL), and 5 days (180.7 +/- 52.3 pg/mL) after the onset of AMI. sIL-6R had biphasic dips at 12 hours (31.1 +/- 4.1 ng/mL) and 3 days (29.9 +/- 1.5 ng/mL) after the onset on AMI. The time-dependent changes in IL-6 paralleled those in sIL-6R from onset to 5 days. Thereafter, the changes in IL-6 and sIL-6R varied; that is, IL-6 gradually decreased from 5 days to 4 weeks, whereas sIL-6R gradually increased from 5 days to 4 weeks. Significant positive correlations were observed between the absolute increase in IL-6 and the decrease in sIL-6R and the changes in white blood cell count, erythrocyte sedimentation rate, C-reactive protein, creatine kinase, and lactic dehydrogenase. Neither IL-6 nor sIL-6R strongly correlated with parameters of coronary atherosclerosis. CONCLUSIONS: These results demonstrate that IL-6 and sIL-6R are associated with the processes of inflammation and myocardial injury during the acute phase of AMI.
BACKGROUND: The plasma level of interleukin-6 (IL-6), a proinflammatory cytokine, has been reported to be elevated in patients with acute myocardial infarction (AMI). In addition to a specific cell-surface IL-6 receptor, a soluble IL-6 receptor (sIL-6R) exists in plasma as an extracellular domain of glycoprotein 80. The pathophysiologic roles of IL-6 and sIL-6R in AMI are still unknown. METHODS AND RESULTS: We measured plasma levels of IL-6 and sIL-6R in 17 patients with AMI to evaluate changes over time at 11 points in the acute phase and compared them with parameters of inflammation, myocardial injury, and atherosclerosis. IL-6 showed a triphasic increase with peaks at 3 hours (276.2 +/- 50.0 pg/mL), 2 days (153.6 +/- 35.7 pg/mL), and 5 days (180.7 +/- 52.3 pg/mL) after the onset of AMI. sIL-6R had biphasic dips at 12 hours (31.1 +/- 4.1 ng/mL) and 3 days (29.9 +/- 1.5 ng/mL) after the onset on AMI. The time-dependent changes in IL-6 paralleled those in sIL-6R from onset to 5 days. Thereafter, the changes in IL-6 and sIL-6R varied; that is, IL-6 gradually decreased from 5 days to 4 weeks, whereas sIL-6R gradually increased from 5 days to 4 weeks. Significant positive correlations were observed between the absolute increase in IL-6 and the decrease in sIL-6R and the changes in white blood cell count, erythrocyte sedimentation rate, C-reactive protein, creatine kinase, and lactic dehydrogenase. Neither IL-6 nor sIL-6R strongly correlated with parameters of coronary atherosclerosis. CONCLUSIONS: These results demonstrate that IL-6 and sIL-6R are associated with the processes of inflammation and myocardial injury during the acute phase of AMI.
Authors: Christopher L Coe; Gayle D Love; Mayumi Karasawa; Norito Kawakami; Shinobu Kitayama; Hazel R Markus; Russell P Tracy; Carol D Ryff Journal: Brain Behav Immun Date: 2010-11-26 Impact factor: 7.217
Authors: L S Rallidis; M G Zolindaki; P C Pentzeridis; K P Poulopoulos; A H Velissaridou; T S Apostolou Journal: Heart Date: 2004-01 Impact factor: 5.994
Authors: Shaoyong Su; Harold Snieder; Andrew H Miller; James Ritchie; J Douglas Bremner; Jack Goldberg; Jun Dai; Linda Jones; Nancy V Murrah; Jinying Zhao; Viola Vaccarino Journal: Atherosclerosis Date: 2008-02-20 Impact factor: 5.162
Authors: Jan-Willem E M Sels; Ellen H A M Elsenberg; Imo E Hoefer; Anton Jan van Zonneveld; Johan Kuiper; J Wouter Jukema; Nico H J Pijls; Gerard Pasterkamp Journal: PLoS One Date: 2012-10-16 Impact factor: 3.240
Authors: M Karaduman; C Oktenli; U Musabak; A Sengul; Z Yesilova; F Cingoz; A Olgun; S Y Sanisoglu; O Baysan; O Yildiz; A Taslipinar; H Tatar; M Kutlu; M Ozata Journal: Clin Exp Immunol Date: 2006-03 Impact factor: 4.330